The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•12 February 2026•

1 min read

DexCom Q4 Earnings: G7 Sensor Performance and Abbott Competition in Focus

A man in a suit over a stock chart with 'Mondelez International' text, surrounded by chocolate, cocoa beans, factories, and shops.

DexCom is set to release its fourth-quarter earnings report, with analysts anticipating earnings per share of $0.6459 on revenues of $1.24 billion. Investors are closely monitoring the performance and market reception of the company's new G7 15-day continuous glucose monitoring (CGM) sensor rollout. This comes amidst increasing competitive pressures from Abbott Laboratories in the rapidly evolving CGM market. The success of the G7 launch is crucial for DexCom to maintain its market position and drive future growth. Furthermore, potential expansion of Medicare coverage for the G7 sensor could significantly bolster the company's outlook. These factors are vital for offsetting competitive headwinds and securing DexCom's long-term trajectory.